Eric Vivier

Eric Vivier was born in Clamart, France. Vivier is a Doctor of Veterinary Medicine (DVM). He graduated from the Ecole Nationale Vétérinaire de Maisons-Alfort and received his doctoral degree in immunology from Paris XI University. He completed postdoctoral training as a Fogarty International Center Research Fellow at Harvard Medical School with Paul J. Anderson and Stuart F. Schlossman at the Dana-Farber Cancer Institute.

Vivier joined Aix-Marseille University as a professor at the Centre d'Immunologie de Marseille-Luminy (CIML) in 1993, becoming its director in 2008 until 2017. He co-founded the biotech company Innate-Pharma in 1999 and in 2014, he co-founded the Marseille-Immunopole, an immunology cluster connecting basic research, therapeutic innovation, and industrial development in the Aix-Marseille region. Vivier was the chief scientific officer of Innate Pharma in January 2018 and in 2022, he served as president of the PSCC (Paris Saclay Cancer Cluster).

Vivier's research has focused on natural killer (NK) cells and innate lymphoid cells (ILCs). His work has contributed to the understanding of the development, function, and therapeutic potential of these cells. His early research investigated the mechanism of inhibitory MHC class I receptors on NK cells and the concept of ITIM-bearing molecules. His group identified the ITAM-bearing polypeptide, KARAP/DAP12/Tyrobp. This research led to the discovery and characterization of ILC3 cells in human and mouse intestines.